News | May 26, 2025
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
These observations are procedural in nature and none of them are related to data integrity
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Subscribe To Our Newsletter & Stay Updated
